NCT01856101 2019-04-10
BEZ235
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Terminated
Clinical Trials
6 trialsNCT01658436 2016-05-02
BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
Novartis
Phase 2 Completed
NCT01628913 2016-04-07
Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors
Novartis
Phase 2 Terminated
NCT01690871 2013-08-02
A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa
Novartis
Phase 2 Withdrawn
NCT01290406 2012-06-21
BEZ235 Trial in Patients With Advanced Endometrial Carcinoma
Novartis
Phase 2 Withdrawn
NCT01288092 2012-06-07
BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer
Novartis
Phase 2 Withdrawn